Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $286.28 million. The enterprise value is $542.60 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.71 million shares outstanding. The number of shares has decreased by -0.47% in one year.
| Current Share Class | 62.71M |
| Shares Outstanding | 62.71M |
| Shares Change (YoY) | -0.47% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 1.43% |
| Owned by Institutions (%) | 14.41% |
| Float | 32.63M |
Valuation Ratios
The trailing PE ratio is 207.51 and the forward PE ratio is 21.78. BIOX's PEG ratio is 1.81.
| PE Ratio | 207.51 |
| Forward PE | 21.78 |
| PS Ratio | 0.76 |
| Forward PS | 0.68 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 13.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 50.85 |
| PEG Ratio | 1.81 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 361.54 |
| EV / Sales | 1.33 |
| EV / EBITDA | 10.66 |
| EV / EBIT | 16.59 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.82.
| Current Ratio | 1.32 |
| Quick Ratio | 0.93 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 5.21 |
| Debt / FCF | n/a |
| Interest Coverage | 1.24 |
Financial Efficiency
Return on equity (ROE) is 0.62% and return on invested capital (ROIC) is 3.40%.
| Return on Equity (ROE) | 0.62% |
| Return on Assets (ROA) | 2.47% |
| Return on Invested Capital (ROIC) | 3.40% |
| Return on Capital Employed (ROCE) | 5.99% |
| Revenue Per Employee | $1.05M |
| Profits Per Employee | $3,858 |
| Employee Count | 389 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 2.06 |
Taxes
| Income Tax | -6.45M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.94% in the last 52 weeks. The beta is 0.73, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -63.94% |
| 50-Day Moving Average | 5.26 |
| 200-Day Moving Average | 7.71 |
| Relative Strength Index (RSI) | 47.25 |
| Average Volume (20 Days) | 349,259 |
Short Selling Information
| Short Interest | 1.10M |
| Short Previous Month | 1.24M |
| Short % of Shares Out | 1.76% |
| Short % of Float | 3.38% |
| Short Ratio (days to cover) | 2.89 |
Income Statement
In the last 12 months, BIOX had revenue of $407.73 million and earned $1.50 million in profits. Earnings per share was $0.02.
| Revenue | 407.73M |
| Gross Profit | 169.42M |
| Operating Income | 32.71M |
| Pretax Income | 9.30M |
| Net Income | 1.50M |
| EBITDA | 50.89M |
| EBIT | 32.71M |
| Earnings Per Share (EPS) | $0.02 |
Full Income StatementBalance Sheet
The company has $31.20 million in cash and $285.64 million in debt, giving a net cash position of -$254.45 million or -$4.06 per share.
| Cash & Cash Equivalents | 31.20M |
| Total Debt | 285.64M |
| Net Cash | -254.45M |
| Net Cash Per Share | -$4.06 |
| Equity (Book Value) | 346.33M |
| Book Value Per Share | 4.94 |
| Working Capital | 93.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $5.67 million and capital expenditures -$7.65 million, giving a free cash flow of -$1.99 million.
| Operating Cash Flow | 5.67M |
| Capital Expenditures | -7.65M |
| Free Cash Flow | -1.99M |
| FCF Per Share | -$0.03 |
Full Cash Flow StatementMargins
Gross margin is 41.55%, with operating and profit margins of 8.02% and 0.37%.
| Gross Margin | 41.55% |
| Operating Margin | 8.02% |
| Pretax Margin | -1.07% |
| Profit Margin | 0.37% |
| EBITDA Margin | 12.48% |
| EBIT Margin | 8.02% |
| FCF Margin | n/a |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.47% |
| Shareholder Yield | 0.47% |
| Earnings Yield | 0.52% |
| FCF Yield | -0.69% |
Analyst Forecast
The average price target for BIOX is $9.88, which is 116.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.88 |
| Price Target Difference | 116.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 7.56% |
| EPS Growth Forecast (5Y) | 80.88% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIOX has an Altman Z-Score of 1.53 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.53 |
| Piotroski F-Score | 6 |